市場調査報告書：骨/関節の再生医療

INTRODUCTION

OBJECTIVES AND GOALS OF STUDY

Regenerative medicine refers to technologies that repair or replace diseased or defective tissues or organs. The main types of regenerative medicine utilize products naturally occurring in the body, such as genes and proteins (antibodies, growth factors, hormones); cells and tissues; embryonic stem cells, and biomaterials. At present, most regenerative medicines on the market fall into the first category and include protein-based drugs and therapies containing human cells. However, there are a few products based on tissue engineering. This technology, which promises to be the most exciting and fastest growing sector of regenerative medicine in the near future, is the primary focus of this report. Tissue engineering technologies discussed include matrices and scaffolds, in vitro and in vivo technologies, and novel materials, which include those utilizing nanotechnology (atomic-scale engineering) of inorganic substances that meld with human tissues.

This report focuses on the bone- and joint-related applications of and markets for the various types of regenerative medicine currently available and projected to be introduced during the forecast period (2001 to 2007). Market drivers discussed include an increase in diseases and disorders that will benefit from these products, primarily arthritis, osteoporosis, and various types of bone and joint trauma (hip fractures, knee injuries, etc.); increasing use of nonautograft products by physicians; and innovative devices that incorporate bone- and cartilage-growth stimulating agents in a regenerative appliance. Products discussed include bone and cartilage grafting and regenerative products derived from autologous, allogeneic and synthetic sources as well as electronic bone growth stimulators and regenerative cartilage products. Profiles of leading and emerging companies in the bone and joint regenerative medicine markets are provided, along with analysis of the current and future positioning of their products and businesses in this active and rapidly changing market.

CONTRIBUTION OF THE STUDY AND FOR WHOM

The aim of this report is to provide an overview of regenerative medicine products available and emerging for the treatment of diseases and disorders of the bones and joints.

The information and analysis presented are an important asset in decision-making for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industries. The study provides a comprehensive analysis of the current markets for regenerative medicine products for bones and joints, relevant applications, and the potential of products in development.

STUDY SCOPE AND FORMAT

The scope of the study is worldwide. The Overview section provides a background of the demographics underlying the market for bone and joint products, a definition of regenerative medicine and the technologies involved, and a discussion of regenerative products in development for applications other than bones and joints.
The Applications section describes the leading bone and joint diseases and disorders applicable to regenerative technologies, including incidence and current methods of treatment.
The section on Products provides extensive descriptions and analysis (including comparative analysis) of regenerative products used to treat bone and joint disorders as well as discussion of products in development.
The section on Industry provides a discussion of regulatory issues affecting regenerative medicine products as well as recent bankruptcies among companies supplying regenerative products and the reasons for their financial difficulties.
The Company Profiles section provides a concise exploration of leading and emerging companies in the area of regenerative products for bones and joints, including product introductions, patents, and overall business strategies.

METHODOLOGY

The base year for this study is 2002. Figures are based on revenue figures at the manufacturer's level and are projected at 2002 dollar values, that is, inflation is not computed into the projection figures.

Information to prepare this study was derived from information provided by chief executive officers, marketing strategists, research executives and others at leading companies involved in the regenerative medicine market. Data was accessed from government agencies and regulatory bodies that monitor and/or regulate medical devices. Searches of secondary material such as company annual reports and 10Ks, journal articles, prospectus assessments, government resources and data from healthcare institutions were also conducted.

INFORMATION SOURCES

The information and analysis presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations.

INTRODUCTION

OBJECTIVES AND GOALS OF STUDY
CONTRIBUTION OF THE STUDY AND FOR WHOM
STUDY SCOPE AND FORMAT
METHODOLOGY
INFORMATION SOURCES
RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
ANALYST CREDENTIALS
BCC ON-LINE SERVICES
- INTERNET

SUMMARY

Summary Table: THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2007 ($ MILLIONS)
Summary Figure: THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2001, 2002 AND 2007 ($ MILLIONS)

OVERVIEW

THE GROWING MARKET FOR REGENERATIVE MEDICINE
WHAT IS REGENERATIVE MEDICINE?
- BIOLOGY-BASED MEDICINE
- APPROACHES USED IN REGENERATIVE MEDICINE
- HUMAN SUBSTANCES
- CELLS AND TISSUES
- EMBRYONIC STEM CELLS
- ADULT STEM CELLS-JUST AS GOOD AS EMBRYONIC STEM CELLS
- SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS
- NOVEL MATERIALS
- GENE THERAPY
THE USE OF BIOREACTORS IN REGENERATIVE MEDICINE
THE IMPACT OF GENOMICS
OTHER AREAS OF PROGRESS IN REGENERATIVE MEDICINE
- CARDIOVASCULAR TECHNOLOGIES
- NEUROLOGICAL TECHNOLOGIES
- SKIN TECHNOLOGIES

APPLICATIONS TO BONE AND JOINT DISEASES AND DISORDERS

MAJOR DISEASES AND CONDITIONS AFFECTING BONES
- OSTEOPOROSIS

Table 1 THE WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2007 ($ MILLIONS)
Table 2 THE WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2007 ($ MILLIONS)
Table 3 HIP FRACTURE VOLUMES, WORLDWIDE, THROUGH 2007
Table 4 HIP FRACTURE VOLUMES, U.S., THROUGH 2007
- TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS
Figure 1 THE U.S. MUSCULOSKELETAL PRODUCTS MARKET, 2002
Figure 2 THE U.S. RECONSTRUCTIVE DEVICE MARKET, 2002
Table 5 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007
Figure 3 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007
Table 6 HIP REPLACEMENT PROCEDURE VOLUMES IN SIX STATES, 2001
Table 7 THE HIP REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
Table 8 THE HIP REPLACEMENT MARKET, U.S., THROUGH 2007 ($ MILLIONS)
Table 9 KNEE REPLACEMENT PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007
Table 10 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007
Figure 4 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007
Table 11 THE KNEE REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
Table 12 THE KNEE REPLACEMENT MARKET, U.S., THROUGH 2007 ($ MILLIONS)
Table 13 THE MARKET FOR UNICONDYLAR KNEE REPLACEMENT, U.S., THROUGH 2007 ($ MILLIONS)
Table 14 SPINAL FUSION PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007
Table 15 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Figure 5 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 16 LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 17 POSTERIOR LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 18 CERVICAL SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Figure 6 THE U.S. SPINAL PRODUCTS MARKET, 2002
Table 19 THE MARKET FOR INTERBODY FUSION DEVICE IMPLANTATION PROCEDURES, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
Table 20 INTERBODY FUSION DEVICE IMPLANTATION PROCEDURE VOLUMES, U.S., THROUGH 2007
- TOTAL BONE REPLACEMENT
- LIMB LENGTHENING
  - LIMB LENGTHENING (CONTINUED)
- DISEASES AFFECTING JOINTS
  - OSTEOARTHRITIS
  - RHEUMATOID ARTHRITIS
Table 21 PREVALENCE OF RHEUMATOID ARTHRITIS, U.S., THROUGH 2007
Table 22 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Table 22 (CONTINUED)
Table 23 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
Figure 7 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, 2001, 2002 AND 2007 ($ MILLIONS)
Table 24 NUMBER OF 2003 TRIALS OF DRUGS TO TREAT RHEUMATOID ARTHRITIS BY MECHANISM OF ACTION

PRODUCTS AND TECHNOLOGIES

REGENERATIVE TECHNOLOGIES
- GENE- AND PROTEIN-BASED APPROACHES
- CELLS AND TISSUES
- EMBRYONIC STEM CELLS
- NOVEL MATERIALS/BIOMATERIALS
REGENERATIVE PRODUCTS TO TREAT BONE DISEASES
- OSTEOBIOLOGICS

Table 25 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, U.S., THROUGH 2007
Table 26 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., THROUGH 2007
Figure 8 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., 2001, 2002 AND 2007
Table 27 COMPARISON OF BONE GRAFT MATERIALS
Table 28 TYPES OF SUBSTITUTE BONE GRAFTS
Table 29 SELECTED DBM PRODUCT AND PERCENTAGE OF DEMINERALIZED BONE MATRIX
Table 30 THE U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2007 ($ MILLIONS)
Table 31 THE WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 ($ MILLIONS)
Table 32 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 ($ MILLIONS)
Figure 9 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, 2001, 2002 AND 2007 ($ MILLIONS)
Table 33 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)
Figure 10 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)
Table 34 THE U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)
Figure 11 SHARE BY COMPANY OF THE NONINVASIVE BONE GROWTH STIMULATOR MARKET, U.S., 2002
- REGENERATIVE PRODUCTS TO TREAT DISEASED AND DAMAGED JOINTS
  - AUTOLOGOUS PRODUCTS
Table 35 THE U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2007 ($ MILLIONS)

INDUSTRY

SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS
PREMARKET NOTIFICATION-510(K)
- WHAT IS PREMARKET NOTIFICATION?
- WHAT IS SUBSTANTIAL EQUIVALENCE?
- WHO IS REQUIRED TO SUBMIT A 510(K)?
- WHEN A 510(K) IS REQUIRED
- WHEN A 501(K) IS NOT REQUIRED
- THE MODERNIZATION ACT AND THE 510(K) SUBMISSION PROCESS-DIFFERENT TYPES OF SUBMISSIONS FOR DIFFERING SITUATIONS
- MEDICAL DEVICES REVIEWED BY THE CENTER FOR BIOLOGIC, EVALUATION, RESEARCH
- THIRD PARTY REVIEW PROGRAM
REGULATORY ISSUES FOR CELLULAR AND TISSUE-BASED PRODUCTS
- CHANGES IN THE REGULATION OF DEMINERALIZED BONE PRODUCTS
- INDUSTRY GROWTH
- ADVANCED TISSUE SCIENCES
- ORGANOGENESIS
- CURIS EXITS THE TISSUE ENGINEERING MARKET
THE TISSUE-ENGINEERING MARKET IN EUROPE
THE DEVELOPMENT OF REGENERATIVE MEDICINES IN JAPAN
- THE DEVELOPMENT … IN JAPAN (CONTINUED)

COMPANY PROFILES

BIOMET ORTHOPEDICS, INC.
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- LEADING PRODUCTS
- CORPORATE STRATEGY
BIOTISSUE TECHNOLOGIES AG
- BUSINESS OVERVIEW
- LEADING PRODUCTS
- CORPORATE STRATEGY
CENTERPULSE, INC.
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- LEADING PRODUCTS
- CORPORATE STRATEGY
CORTEK, INC.
- BUSINESS OVERVIEW
- LEADING PRODUCTS
- CORPORATE STRATEGY
CURIS, INC.
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- LEADING PRODUCTS
- CORPORATE STRATEGY
GENSCI REGENERATION SCIENCES INC.
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- LEADING PRODUCTS
- CORPORATE STRATEGY
GENZYME BIOSURGERY
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- LEADING PRODUCTS
- CORPORATE STRATEGY
INTEGRA LIFESCIENCES HOLDINGS CORP.
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- LEADING PRODUCTS
- CORPORATE STRATEGY
INTERPORE CROSS INTERNATIONAL
- BUSINESS OVERVIEW
- FINANCIAL INFORMATION
- LEADING PRODUCTS

Table 36 INTERPORE CROSS'S MARKETED ORTHOBIOLOGIC PRODUCTS
Table 37 INTERPORE CROSS'S NEAR-TERM PRODUCT PIPELINE
- ISOTIS BV
  - BUSINESS OVERVIEW
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- ISTO TECHNOLOGIES, INC.
  - BUSINESS OVERVIEW
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- MEDTRONIC, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- MILLENIUM BIOLOGIX INC.
  - BUSINESS OVERVIEW
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- NEUCOLL INC.
  - BUSINESS OVERVIEW
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- ORQUEST, INC.
  - BUSINESS OVERVIEW
  - LEADING PRODUCTS
Table 38 ORQUEST'S PRODUCT PIPELINE
- ORTHOFIX INTERNATIONAL N.V.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- ORTHOLOGIC CORP.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- ORTHOVITA, INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
Table 39 ORTHOVITA'S PRODUCT PIPELINE
- OSTEOBIOLOGICS, INC.
  - BUSINESS OVERVIEW
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
Table 40 OSTEOBIOLOGICS' PATENT PORTFOLIO
- OSTEOTECH INC.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- REGEN BIOLOGICS, INC.
  - BUSINESS OVERVIEW
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- STRYKER CORP.
  - BUSINESS OVERVIEW
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- TIGENIX N.V.
  - BUSINESS OVERVIEW
  - LEADING PRODUCTS
  - CORPORATE STRATEGY
- WRIGHT MEDICAL GROUP, INC.
  - FINANCIAL INFORMATION
  - LEADING PRODUCTS
  - CORPORATE STRATEGY

LIST OF TABLES

Summary Table: THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2007 ($ MILLIONS)
Table 1 THE WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2007 ($ MILLIONS)
Table 2 THE WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2007 ($ MILLIONS)
Table 3 HIP FRACTURE VOLUMES, WORLDWIDE, THROUGH 2007
Table 4 HIP FRACTURE VOLUMES, U.S., THROUGH 2007
Table 5 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 6 HIP REPLACEMENT PROCEDURE VOLUMES IN SIX STATES, 2001
Table 7 THE HIP REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
Table 8 THE HIP REPLACEMENT MARKET, U.S., THROUGH 2007 ($ MILLIONS)
Table 9 KNEE REPLACEMENT PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007
Table 10 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 11 THE KNEE REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
Table 12 THE KNEE REPLACEMENT MARKET, U.S., THROUGH 2007 ($ MILLIONS)
Table 13 THE MARKET FOR UNICONDYLAR KNEE REPLACEMENT, U.S., THROUGH 2007 ($ MILLIONS)
Table 14 SPINAL FUSION PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007
Table 15 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 16 LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 17 POSTERIOR LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 18 CERVICAL SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 19 THE MARKET FOR INTERBODY FUSION DEVICE IMPLANTATION PROCEDURES, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
Table 20 INTERBODY FUSION DEVICE IMPLANTATION PROCEDURE VOLUMES, U.S., THROUGH 2007
Table 21 PREVALENCE OF RHEUMATOID ARTHRITIS, U.S., THROUGH 2007
Table 22 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
Table 23 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, THROUGH 2007 ($ MILLIONS)
Table 24 NUMBER OF 2003 TRIALS OF DRUGS TO TREAT RHEUMATOID ARTHRITIS BY MECHANISM OF ACTION
Table 25 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, U.S., THROUGH 2007
Table 26 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., THROUGH 2007
Table 27 COMPARISON OF BONE GRAFT MATERIALS
Table 28 TYPES OF SUBSTITUTE BONE GRAFTS
Table 29 SELECTED DBM PRODUCT AND PERCENTAGE OF DEMINERALIZED BONE MATRIX
Table 30 THE U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2007 ($ MILLIONS)
Table 31 THE WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 ($ MILLIONS)
Table 32 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 ($ MILLIONS)
Table 33 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)
Table 34 THE U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)
Table 35 THE U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2007 ($ MILLIONS)
Table 36 INTERPORE CROSS'S MARKETED ORTHOBIOLOGIC PRODUCTS
Table 37 INTERPORE CROSS'S NEAR-TERM PRODUCT PIPELINE
Table 38 ORQUEST'S PRODUCT PIPELINE
Table 39 ORTHOVITA'S PRODUCT PIPELINE
Table 40 OSTEOBIOLOGICS' PATENT PORTFOLIO

LIST OF FIGURES

Summary Figure: THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2001, 2002 AND 2007 ($ MILLIONS)
Figure 1 THE U.S. MUSCULOSKELETAL PRODUCTS MARKET, 2002
Figure 2 THE U.S. RECONSTRUCTIVE DEVICE MARKET, 2002
Figure 3 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007
Figure 4 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007
Figure 5 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007
Figure 6 THE U.S. SPINAL PRODUCTS MARKET, 2002
Figure 7 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, 2001, 2002 AND 2007 ($ MILLIONS)
Figure 8 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., 2001, 2002 AND 2007
Figure 9 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, 2001, 2002 AND 2007 ($ MILLIONS)
Figure 10 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS)
Figure 11 SHARE BY COMPANY OF THE NONINVASIVE BONE GROWTH STIMULATOR MARKET, U.S., 2002

再生医療：骨および関節

Regenerative Medicines: Bone and Joint Applications

LIST OF TABLES

LIST OF FIGURES